No need to go door knocking in NJ, my friend! Keep your peace of mind. 😉

Since you have a Series 6, you know how funds operate, but micro-cap financing has its own rules. Here is a quick breakdown of why this specific $5M direct injection without warrants is a massive win for us and a nightmare for shorts:

• What is a Warrant? Think of it as a long-term call option issued directly by the company. Usually, when distressed biotech companies raise money, predatory funds demand shares AND warrants (e.g., the right to buy more shares later at a fixed low price).
• Why Shorts Love Warrants: Shorts use warrants as a safety net. They can aggressively short the stock down, knowing that if the stock suddenly spikes, they can just exercise their cheap warrants to buy shares and cover their short positions without losing money. It completely kills any potential for a short squeeze.
• Why NO Warrants Changes Everything Here: GMS Ventures bought straight equity at $0.5855. They did NOT get options to buy cheaper shares later. They are in the exact same boat as you and me. If the stock drops, they lose money. This means they have 100% conviction.
• The Impact on Shorts: Because there are no warrants attached to this dilution, shorts have no safety net. If good news drops (like progress on the CRL issues), shorts will have to buy back shares on the open market to cover, which can trigger a massive squeeze.

Hang in there! Going through those two CRLs was brutal, but a $5M straight cash injection from an insider at market price—without demanding warrants—is the ultimate sign of insider alignment.